Skip to main content

Notice of the 2026 Annual General Meeting of the Shareholders of Theon International PLC

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)13 May 2026 – Theon International Plc (THEON) announces that its Annual General Meeting for the year 2026 (the AGM) will be held at the Amara Hotel, 95 Amathus Avenue, Agios Tychonas, 4533 Limassol, Cyprus, on 4 June 2026, starting at 14:00 hours (Local Time), 12:00 hours (UK Time). The Notice of AGM is available on the Company’s website.For inquiries, please contact:Investor RelationsNikos MalesiotisE-Mail: ir@theon.comTel: +30 210 6772290 Media ContactElli MichouE-Mail: press@theon.comTel: +30 210 6728610About THEON GROUP THEON GROUP of companies develops and manufactures cutting-edge night vision and thermal imaging systems for Defense and Security applications with a global footprint. THEON GROUP started its operations in 1997 from Greece and today occupies a leading...

Continue reading

Reminder to register: Invitation to Multitude AG’s Q1 2026 Results Presentation – Join us virtually on 21 May

Zug, 13 May 2026 – Multitude AG, a listed European FinTech company, offering digital lending and online banking services to consumers, SMEs, and institutional clients, (“Multitude”, “Company” or “Group”) warmly invites financial analysts, investors, and media to its Q1 2026 Results Presentation webcast. The event will be held virtually on Thursday, 21 May 2026, at 10:00 am CEST.  Please follow the link to register for the webcast: https://multitude.events.inderes.com/q1-2026/register Contact: Adam Hansson TönningHead of IR and TreasuryPhone: +46733583171E-Mail: adam.tonning@multitude.com   About Multitude AG: Multitude is a listed European FinTech company, offering digital lending and online banking services to consumers, SMEs, and institutional clients, overlooked by traditional banks. The services are provided through three independent...

Continue reading

Interim report of Copenhagen Airports A/S (CPH) for the period 1 January – 31 March 2026

The Board of Directors has today approved the interim report for the period 1 January – 31 March 2026. COPENHAGEN AIRPORTS A/SP.O. Box 74Lufthavnsboulevarden 6DK-2770 Kastrup Contact:Rasmus LundCFO Telephone: +45 32312800E-mail: cphpresse@cph.dkwww.cph.dkCVR no. 14 70 72 04AttachmentsQ1 2026 Report of Copenhagen Airports UKInterim report of Copenhagen Airports A-S (CPH) for the period 1 January – 31 March 2026

Continue reading

Crown Point Announces Operating and Financial Results for the Three Months Ended March 31, 2026

CALGARY, Alberta, May 13, 2026 (GLOBE NEWSWIRE) — TSX-V: CWV: Crown Point Energy Inc. (“Crown Point”, the “Company”, “our” or “we“) today announced its financial and operating results for the three months ended March 31, 2026. All dollar figures are expressed in United States dollars (“USD”) unless otherwise stated. In the following discussion, the three months ended March 31, 2026 may be referred to as “Q1 2026” and the three months ended March 31, 2025 may be referred to as “Q1 2025”. Q1 2026 SUMMARY During Q1 2026, the Company:Reported net cash and funds flow provided by operating activities of $6.5 million and $11.7 million, respectively, as compared to Q1 2025 when the Company reported net cash provided by operating activities and funds flow used in operating activities of $3.1 million...

Continue reading

Table Trac, Inc. Reports 2026 First Quarter Earnings

MINNETONKA, Minn., May 13, 2026 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos, announced financial results for the three months ending March 31, 2026. The 10-Q can be found @ http://www.sec.gov First Quarter 2026 HighlightsThe Company installed three systems at new customer locations and expanded the services at three of our existing customers. The Company had three customers with system contracts in backlog as of March 31, 2026. The company anticipates that all of these contracts will be installed during the second quarter of 2026.First Quarter 2026 Financial ResultsSystem revenue increased from $1.56M in 2025 to approximately $1.74M in 2026. Maintenance revenues increased from $1.51M in 2025 to...

Continue reading

Verde AgriTech Announces Q1 2026 Financial and Operating Results

BELO HORIZONTE, Brazil and SINGAPORE, May 13, 2026 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: NPK | OTCQX: VNPKF) (“Verde” or the “Company”), today reported its financial results for the period ended March 31, 2026 (“Q1 2026”). “Q1 2026 showed the value of discipline in a credit-constrained Brazilian agricultural market. Verde chose to prioritize liquidity, receivables quality and higher-quality counterparties over higher-risk volume. That approach reduced short-term sales, but it also supported a modest year-over-year improvement in EBITDA before non-cash events, a near-zero expected credit loss allowance and a stronger cash position following the brokered private placement completed in March 2026,” stated Cristiano Veloso, Founder and CEO of Verde. “We are also taking decisive actions to align the cost base with current...

Continue reading

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with the FDA to ensure CMC readiness for accelerated clinical timelines Clinical data presented at Pediatric Rheumatology Symposium 2026 and Congress of Clinical Rheumatology – East 2026 highlights safety and efficacy of single dose of FT819 with reduced conditioning in SLE Preclinical data presented at the American Association for Cancer Research 2026 demonstrates the unique ability of FT839 for comprehensive targeting of hematological malignancies and autoimmune diseases without the use of conditioning...

Continue reading

SS Innovations Reports First Quarter 2026 Financial Results

Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures FORT LAUDERDALE, Fla., May 13, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026. First Quarter 2026 OverviewRevenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025. Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025. Gross profit rose 390.0% to $5.3...

Continue reading

Lite Strategy Reports Fiscal 2026 Third Quarter Results

Lite Strategy Continues to Deliver Recurring Yield on Litecoin Holdings and Advance Share Repurchase Program SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) — Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 third quarter ended March 31, 2026. Business and Financial Highlights:Active Treasury Management: Successfully continued the Company’s covered call option program, generating $0.7 million in net proceeds since October 2025 and further demonstrating Lite Strategy’s ability to transform its LTC holdings into a yield-generating reserve asset and differentiate itself from passive investment vehicles. Share Repurchase Program: Deployed covered call proceeds and 35,250...

Continue reading

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren’s disease Cash and investment balance of $491.5 million as of March 31, 2026 expected to provide runway into early 2029 BOSTON, May 13, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “We had another quarter of solid execution for our two global Phase 3 programs in generalized myasthenia gravis and primary Sjögren’s disease, both of which are progressing as planned,” said Jean-Paul Kress, M.D., Chief Executive...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.